52-86-8 LNEPOXFFQSENCJ-UHFFFAOYSA-N LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol 1-Butanone, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)- 1-(3-p-Fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine 4-(4-Hydroxy-4'-chloro-4-phenylpiperidino)-4'-fluorobutyrophenone 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone Aloperidin Bioperidolo Brotopon Butyrophenone, 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4'-fluoro- Einalon S Eukystol Haloperin Halosten Keselan McN-JR 1625 Neurodol NSC 170973 NSC 615296 Peluces Serenace Serenase Serenelfi Sigaperidol γ-[4-(p-Chlorphenyl)-4-hydroxypiperidino]-p-fluorbutyrophenone DTXSID4034150 50-55-5 QEVHRUUCFGRFIF-MDEJGZGSSA-N QEVHRUUCFGRFIF-MDEJGZGSSA-N Reserpine Yohimban-16-carboxylic acid, 11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester, (3β,16β,17α,18β,20α)- (-)-Reserpine 11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester 3,4,5-Trimethoxybenzoyl methyl reserpate 3β,20α-Yohimban-16β-carboxylic acid, 18β-hydroxy-11,17α-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate Apoplon Banasil Bioserpine Carpacil Crystoserpine Deserpine Elserpine Eserpine Eskaserp Hiposerpil Lemiserp Loweserp Mayserpine NSC 237659 NSC 59272 Quiescin Raunervil Raupasil Raurine Rau-sed Rausedil Rausedyl Rausingle Rauwasedin Resercaps Resercen Reserlor Reserpamed Reserpex Reserpil Reserpin reserpina Reserpoid Respital Restran Riserpa Rivasin Roxinoid Sandril Sedaraupin Sedserp Serolfia Serp-AFD Serpaloid Serpanray Serpasil Serpasil premix Serpasil Serpasol Serpasol Serpate Serpentina Serpicon Serpiloid Serpine Serpipur Sertabs Sertina Temposerpine Triserpin Vio-Serpine DTXSID7021237 CL:0000700 CL dopaminergic neuron PR:000013246 PR prolactin UBERON:0001911 UBERON mammary gland D000236 MESH Adenoma D002277 MESH Carcinoma GO:0001963 GO synaptic transmission, dopaminergic GO:0070459 GO prolactin secretion D006965 MESH hyperplasia MP:0010307 MP abnormal tumor latency 1 WIKI increased Haloperidol 2016-11-29T18:42:27 2016-11-29T18:42:27 Reserpine 2016-11-29T18:42:27 2016-11-29T18:42:27 10116 NCBI SD rat Decreased, Dopaminergic activity Cellular AOPWiki 2016-11-29T18:41:29 2016-12-03T16:37:53 Increased, prolactin secretion Tissue AOPWiki 2016-11-29T18:41:29 2016-12-03T16:37:53 Increased, hyperplasia (mammary gland) Tissue UBERON:0001911 UBERON mammary gland AOPWiki 2016-11-29T18:41:29 2017-09-16T10:17:14 Increased, latency period Individual AOPWiki 2016-11-29T18:41:29 2016-12-03T16:37:53 Increased, Adenomas/carcinomas (mammary) Tissue UBERON:0001911 UBERON mammary gland AOPWiki 2016-11-29T18:41:29 2017-09-16T10:17:12 AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 Anti-dopaminergic activity and mammary tumors Charles Wood <p>Cancer AOP Workgroup. National Health and Environmental Effects Research Laboratory, Office of Research and Development, Integrated Systems Toxicology Division, US Environmental Protection Agency, Research Triangle Park, NC. Corresponding author for wiki entry (wood.charles@epa.gov)</p> BY-SA 1.0 <p>This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.</p> adjacent Not Specified High non-adjacent Not Specified High non-adjacent Not Specified Moderate non-adjacent Not Specified Moderate non-adjacent Not Specified Moderate High Female High Not Specified Not Specified <p>1. O&#39;Connor, J. C., Davis, L. G., Frame, S. R., and Cook, J. C. (2000). Detection of dopaminergic modulators in a tier I screening battery for identifying endocrine-active compounds (EACs). Reproductive toxicology 14(3), 193-205.</p> <p>2. Rudmann, D., Cardiff, R., Chouinard, L., Goodman, D., Kuttler, K., Marxfeld, H., Molinolo, A., Treumann, S., Yoshizawa, K., Inhand Mammary, Z. s. P., and Clitoral Gland Organ Working, G. (2012). Proliferative and nonproliferative lesions of the rat and mouse mammary, Zymbal&#39;s, preputial, and clitoral glands. Toxicologic pathology 40(6 Suppl), 7S-39S, 10.1177/0192623312454242.</p> AOPWiki 2016-11-29T18:41:17 2026-01-11T16:56:07